Anbio Biotechnology (NASDAQ:NNNN) Sees Large Growth in Short Interest

Anbio Biotechnology (NASDAQ:NNNN) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 58,423 shares, an increase of 122.9% from the August 15th total of 26,210 shares. Based on an average trading volume of 286,803 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company’s stock are sold short.

Anbio Biotechnology Stock Performance

Shares of NASDAQ NNNN traded down $0.01 during trading on Monday, reaching $6.33. 31,269 shares of the company traded hands, compared to its average volume of 69,414. The firm has a 50 day simple moving average of $8.99 and a 200-day simple moving average of $18.73. Anbio Biotechnology has a 52-week low of $6.13 and a 52-week high of $51.33.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.